A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain — ENHANCE

Brain Pathology Clinical Trial

Official title:
Phase IV, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.10 Mmol/kg of MultiHance With 0.10 Omniscan in Magnetic Resonance Imaging (MRI) of the Brain

Status Completed

Clinical Trial Summary

This study aims at a direct comparison between Multihance and a validated comparator like Omniscan in a cross-over individual design in patients with brain tumors to confirm the superior overall diagnostic performance of MuliHance for this indication

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind

Related Conditions & MeSH terms

Brain Pathology

Clinical Trial Details

NCT number	NCT00323102
Study type	Interventional
Source	Bracco Diagnostics, Inc
Contact
Status	Completed
Phase	Phase 4
Start date	May 2006
Completion date	March 2007

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03696082` - A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines	N/A
Active, not recruiting	`NCT06040580` - Can we Use Resting-state fMRI and CSD Fiber Tractography for Presurgical Mapping?
Completed	`NCT05946928` - EMERGENCE AGITATION After Premedication IN PAEDIATRIC MAGNETIC RESONANCE IMAGING: A RETROSPECTIVE COHORT STUDY
Terminated	`NCT03494855` - Evaluating the Efficacy of SyMRI in Clinical Pediatric Populations
Recruiting	`NCT03593330` - Neurosurgical Transitional Care Programme	N/A